JAMA Pediatr:超400万儿童人口队列研究显示,短期口服皮质类固醇激素对儿童有潜在危害

2021-04-26 MedSci原创 MedSci原创

在开始皮质类固醇治疗后的第一个月内,糖皮质激素爆发与胃肠道出血、脓毒症和肺炎增加1.4- 2.2倍显著相关,但与青光眼无关。

Pixabay.com

根据国际指南的建议,口服皮质类固醇是治疗多种炎症性疾病的基础,如类风湿性关节炎、炎症性肠病和哮喘。半个多世纪以来,人们已经认识到长期使用口服皮质类固醇与随后的不良事件有关,包括类丘疹、胃肠道出血、感染、青光眼、高血糖、血管疾病和骨质疏松症等。因此,临床医生告诫不要长期使用口服皮质类固醇,除非潜在的好处大于潜在的风险。

目前,美国21%的普通成年人和法国17%的普通成年人接受短期口服皮质类固醇治疗。皮质类固醇短期口服治疗通常用于治疗无生命危险的疾病,如上呼吸道感染、支气管炎、皮疹和腰痛。然而,有关儿童短期口服皮质类固醇的潜在危害的数据仍然有限。为了量化儿童糖皮质激素暴发与严重不良事件的关系,包括胃肠道出血、脓毒症、肺炎和青光眼。有研究者进行了相关研究,研究结果发表在JAMA Pediatrics杂志上。

这项队列研究使用来自台湾健康保险研究数据库2013年1月1日至2017年12月31日的数据,研究对象为18岁以下的儿童,采用自我控制的病例系列设计。数据分析时间为2020年1月1日至7月30日。主要结局是计算4种严重不良事件(胃肠道出血、脓毒症、肺炎和青光眼)的发生率。

研究结果显示,在4542623名儿童中,23%的儿童服用单一皮质类固醇。最常见的适应症是急性呼吸道感染和过敏性疾病。单次使用皮质类固醇的儿童与未使用皮质类固醇的儿童每1000人-年的发病率差异:胃肠道出血为0.60,败血症为0.03,肺炎为9.35,青光眼为0.01。激素冲击后5~30天内,胃肠道出血、脓毒症、肺炎和青光眼的概率分别为1.41、2.02、2.19和0.98;在随后的31至90天内,胃肠道出血的发生率为1.10,败血症为1.08,肺炎为1.09,青光眼为0.95。

暴露于皮质类固醇与儿童胃肠道出血、脓毒症、肺炎和青光眼之间的相关性

在这项超过400万儿童的人口队列研究中,42%的儿童在5年的研究期间至少暴露于1种皮质类固醇。急性呼吸道感染(34%)和过敏性疾病(31%)的儿童通常使用皮质类固醇。在开始皮质类固醇治疗后的第一个月内,糖皮质激素爆发与胃肠道出血、脓毒症和肺炎增加1.4- 2.2倍显著相关,但与青光眼无关。这项研究证明了给儿童开皮质类固醇的潜在危害,并呼吁谨慎使用皮质类固醇。

总之,期口服糖皮质激素通常被用于非危及生命的疾病,包括急性呼吸道感染和过敏性疾病。临床医生应意识到这些罕见但潜在严重的不良事件。这些发现为临床医生和指南开发者提供了现实世界的证据,以实现最佳的风险效益比策略,预防儿童使用皮质类固醇所造成的危害。

参考文献:Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021. doi:10.1001/jamapediatrics.2021.0433

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639752, encodeId=18d61639e5299, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 10 12:50:52 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954590, encodeId=933a1954590c6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Nov 02 11:50:52 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728920, encodeId=89fb1e289206c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Nov 13 07:50:52 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313467, encodeId=c21e131346ec4, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 28 07:50:52 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036589, encodeId=ce31103658949, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Apr 26 19:50:52 CST 2021, time=2021-04-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1639752, encodeId=18d61639e5299, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 10 12:50:52 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954590, encodeId=933a1954590c6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Nov 02 11:50:52 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728920, encodeId=89fb1e289206c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Nov 13 07:50:52 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313467, encodeId=c21e131346ec4, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 28 07:50:52 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036589, encodeId=ce31103658949, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Apr 26 19:50:52 CST 2021, time=2021-04-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1639752, encodeId=18d61639e5299, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 10 12:50:52 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954590, encodeId=933a1954590c6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Nov 02 11:50:52 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728920, encodeId=89fb1e289206c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Nov 13 07:50:52 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313467, encodeId=c21e131346ec4, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 28 07:50:52 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036589, encodeId=ce31103658949, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Apr 26 19:50:52 CST 2021, time=2021-04-26, status=1, ipAttribution=)]
    2021-11-13 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1639752, encodeId=18d61639e5299, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 10 12:50:52 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954590, encodeId=933a1954590c6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Nov 02 11:50:52 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728920, encodeId=89fb1e289206c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Nov 13 07:50:52 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313467, encodeId=c21e131346ec4, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 28 07:50:52 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036589, encodeId=ce31103658949, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Apr 26 19:50:52 CST 2021, time=2021-04-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1639752, encodeId=18d61639e5299, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 10 12:50:52 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954590, encodeId=933a1954590c6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Nov 02 11:50:52 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728920, encodeId=89fb1e289206c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Nov 13 07:50:52 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313467, encodeId=c21e131346ec4, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Apr 28 07:50:52 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036589, encodeId=ce31103658949, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Apr 26 19:50:52 CST 2021, time=2021-04-26, status=1, ipAttribution=)]
    2021-04-26 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

打破儿童用药瓶颈 顶层设计支持与供给侧改革需联动

落实健康中国的国家战略,聚焦我国儿童新药研发创制和儿童安全用药两大问题,3月31日,以“儿童要用儿童药”为主题,由中国医药峰会组委会、中国农工民主党中央生物技术与药学工作委员会、中国药理学会等主办,葵花药业集团有限公司等承办的2018中国儿童安全用药大会于北京召开。

两岁女童服药后突然离世,给全体医生敲响警钟!

在儿童用药方面,广大基层医生一定要警慎。

CDE公开征求意见:儿童用药研究如何使用真实世界证据

5月18日,国家药监局药品审评中心发布通知,就《真实世界证据支持儿童药物研发与审评的技术指导原则(征求意见稿)》(以下简称指导原则)公开征求意见。征求意见时间为期一个月。

人大代表:儿童用药不良反应率是成人4倍

全国人大代表建议:制定专门儿童用药保障法规。

这37个药被纳入第三批鼓励研发申报儿童药品清单

近日,国家卫生健康委、工业和信息化部、国家药品监管局围绕我国儿童疾病谱以及相关企业研发生产能力,组织国家卫生健康委儿童用药专家委员会等有关专家结合中国大陆境内尚未注册上市且临床急需的儿童用药现状,基于循证原则筛选论证,并充分听取了相关专业学(协)会意见,提出了《第三批鼓励研发申报儿童药品建议清单》,并进行了公示,此次第三批鼓励研发清单共计纳入37个药品,具体包括地西泮口服液、利多卡因喷雾剂、西地那

儿童用药方法小常识

“这瓶美林是坏的,打不开,麻烦帮我换一瓶?” “医生怎么回事,我家宝宝这么小,哪能吞下这个大的药片?” “这个吸入剂看上去这么复杂,咋用?”